Related Experiment Video
Updated: Oct 27, 2026
COVID-19 Seroprevalence Test for IgG Antibody Levels Among Healthy Donors Across Different Pandemic Phases in Jeddah
Published on: June 24, 2025
Association Between ABO Blood Group and Survival Outcomes in Advanced NSCLC Treated with Immune Checkpoint Inhibitors
Hilal Karakaş1, Safa Can Efil1, Burak Bilgin1
1Department of Medical Oncology, Ankara Bilkent City Hospital, Ankara 06800, Türkiye.
Background:
Reliable biomarkers that predict outcomes with immune checkpoint inhibitors (ICIs) in non-small cell lung cancer (NSCLC) remain limited. ABO blood group antigens may influence tumor immunity and response to immunotherapy.
Methods:
We retrospectively analyzed 239 patients with advanced NSCLC treated with ICI-based therapy between 2019 and 2024. Patients were classified according to ABO blood group, and overall survival (OS), progression-free survival (PFS), and treatment response were evaluated.
Results:
Patients with blood group O had significantly longer OS (18.6 vs. 11.0 months; p < 0.001) and PFS (9.4 vs. 4.2 months; p = 0.001) than patients with non-O blood groups. In multivariable analyses, blood group O remained independently associated with improved OS and PFS.
Conclusions:
Blood group O may represent a simple and readily available host-related prognostic marker in patients with advanced NSCLC receiving ICI-based therapy. Prospective multicenter studies are required to validate these findings.